Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: Results of the TARGET study

Keith Henry, Robert J. Wallace, Paul C. Bellman, Dorece Norris, Robin L. Fisher, Lisa L. Ross, Qiming Liao, Mark S. Shaefer

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: Results of the TARGET study'. Together they form a unique fingerprint.

Medicine & Life Sciences